MX2023001041A - Anticuerpo anti-lilrb1 y usos del mismo. - Google Patents

Anticuerpo anti-lilrb1 y usos del mismo.

Info

Publication number
MX2023001041A
MX2023001041A MX2023001041A MX2023001041A MX2023001041A MX 2023001041 A MX2023001041 A MX 2023001041A MX 2023001041 A MX2023001041 A MX 2023001041A MX 2023001041 A MX2023001041 A MX 2023001041A MX 2023001041 A MX2023001041 A MX 2023001041A
Authority
MX
Mexico
Prior art keywords
lilrb1
lilrb1 antibody
antibody
antigen
specifically
Prior art date
Application number
MX2023001041A
Other languages
English (en)
Inventor
Yoon Aa Choi
kim jung A
Han Byul Kim
Shinyoung Kang
Heehang Kim
Minsoon Kim
Junhaeng Cho
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2023001041A publication Critical patent/MX2023001041A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un anticuerpo anti-LILRB1 que tiene una especificidad aumentada para LILRB1, y a los usos del mismo. Específicamente, se proporcionan un anticuerpo anti-LILRB1 o un fragmento de unión a antígeno del mismo, y usos de los mismos en el tratamiento de cáncer.
MX2023001041A 2020-07-28 2021-07-27 Anticuerpo anti-lilrb1 y usos del mismo. MX2023001041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200094053 2020-07-28
PCT/KR2021/009696 WO2022025585A1 (ko) 2020-07-28 2021-07-27 항-lilrb1 항체 및 그의 용도

Publications (1)

Publication Number Publication Date
MX2023001041A true MX2023001041A (es) 2023-02-16

Family

ID=80036572

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001041A MX2023001041A (es) 2020-07-28 2021-07-27 Anticuerpo anti-lilrb1 y usos del mismo.

Country Status (12)

Country Link
US (1) US20230374127A1 (es)
EP (1) EP4169950A4 (es)
KR (1) KR20220014316A (es)
CN (1) CN115867353A (es)
AU (1) AU2021315366A1 (es)
BR (1) BR112022026922A2 (es)
CA (1) CA3186256A1 (es)
IL (1) IL299942A (es)
MX (1) MX2023001041A (es)
TW (2) TW202208438A (es)
WO (1) WO2022025585A1 (es)
ZA (1) ZA202213434B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023170434A1 (en) 2022-03-11 2023-09-14 Macomics Limited Compositions and methods for modulation of macrophage activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101038126B1 (ko) 2010-11-30 2011-05-31 주식회사 엘지생명과학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
WO2013181438A2 (en) * 2012-05-30 2013-12-05 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating pro-inflammatory immune response
MX2018001522A (es) * 2015-08-05 2018-03-15 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos.
WO2018022881A2 (en) * 2016-07-29 2018-02-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
US20210122819A1 (en) * 2018-01-18 2021-04-29 Adanate, Inc. Anti-lilrb antibodies and uses thereof
EP3902828A1 (en) * 2018-12-26 2021-11-03 Innate Pharma Compounds and methods for treatment of head and neck cancer
WO2021028921A1 (en) * 2019-08-12 2021-02-18 Biond Biologics Ltd. Antibodies against ilt2 and use thereof
CA3161827A1 (en) * 2019-12-23 2021-07-01 Yoon Aa Choi Anti-lilrb1 antibody and uses thereof

Also Published As

Publication number Publication date
CA3186256A1 (en) 2022-02-03
AU2021315366A1 (en) 2023-02-02
EP4169950A4 (en) 2024-03-20
IL299942A (en) 2023-03-01
TW202208438A (zh) 2022-03-01
BR112022026922A2 (pt) 2023-02-07
AU2021315366A9 (en) 2023-06-29
KR20220014316A (ko) 2022-02-04
CN115867353A (zh) 2023-03-28
JP2023537225A (ja) 2023-08-31
WO2022025585A1 (ko) 2022-02-03
TW202340258A (zh) 2023-10-16
US20230374127A1 (en) 2023-11-23
ZA202213434B (en) 2024-04-24
EP4169950A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
TN2019000272A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
ATE461220T1 (de) Anti-egfr-antikörper
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
NZ594682A (en) Fully human antibodies specific to cadm1
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
MX2022000111A (es) Moleculas de union a claudina-6 y usos de las mismas.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
CR20230469A (es) Anticuerpos anti-nectina-4 y usos de los mismos
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
MX2022005717A (es) Moleculas de anticuerpos anti-siglec-9.
MX2020013450A (es) Materiales y métodos para tratar el cancer y los trastornos relacionados con el estrés.